Reuters logo
BRIEF-GlaxoSmithKline announces positive results for asthma drug study
May 5, 2017 / 11:51 AM / in 5 months

BRIEF-GlaxoSmithKline announces positive results for asthma drug study

May 5 (Reuters) - Glaxosmithkline Plc:

* Announced positive results from innovative Salford Lung Study (SLS) in asthma

* Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care

* Study showed significantly more asthma patients initiated on treatment with Relvar Ellipta achieved improvement in their asthma control

* At 24 weeks a significantly higher percentage of patients with asthma achieved better control of their asthma (71 pct) measured by asthma control test (ACT)

* Statistically significant findings were also seen at 12, 40 and 52 weeks

* Serious adverse events of pneumonia by randomised group were reported by 39 patients (ff/vi arm 23, 1 pct; usual care arm 16, <1 pct) Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below